Year in Review: Updates in Treating Myelofibrosis : Episode 10
Selection and Sequencing of JAK Inhibitors for Patients With MF
Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice.
EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF
EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
EP: 7.Future Directions in Combination Therapies for Myelofibrosis
EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
Now Viewing
EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF
EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis
EP: 12.Emerging Treatments for Myelofibrosis
Related Videos
Related Content
